MLYS
Mineralys Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.24
−0.65%0
Insider buys (3m)
6
Insider sells (3m)
-$5.5M
Net value (3m)
-18.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Oct 20, 2026 | COATS LONNEL · director | A-Award | 16,600 | $21 |
| Oct 20, 2026 | Peterson Kristine · director | A-Award | 12,400 | $0.00 |
| Oct 20, 2026 | Peterson Kristine · director | A-Award | 16,600 | $21 |
| Oct 20, 2026 | COATS LONNEL · director | A-Award | 12,400 | $0.00 |
| Oct 2, 2026 | Congleton Jon · director, officer: Chief Executive Officer | Sale | 75,000 | $25 |
| Sep 24, 2026 | Slingsby Brian Taylor · director | Sale | 104,320 | $29 |
| Sep 22, 2026 | Warren Eric · officer: Chief Commercial Officer | Sale | 7,438 | $28 |
| Sep 22, 2026 | Warren Eric · officer: Chief Commercial Officer | M-Exempt | 7,438 | $13 |
| Sep 17, 2026 | Karydas Daphne · director | Sale | 3,000 | $29 |
| Sep 17, 2026 | Karydas Daphne · director | M-Exempt | 3,000 | $12 |
| Aug 25, 2026 | Warren Eric · officer: Chief Commercial Officer | M-Exempt | 7,437 | $13 |
| Aug 25, 2026 | Warren Eric · officer: Chief Commercial Officer | Sale | 7,437 | $26 |
| Aug 12, 2026 | Rodman David Malcom · officer: Chief Medical Officer | M-Exempt | 2,170 | $16 |
| Aug 12, 2026 | Ferguson James J. III · officer: Chief Medical Officer | A-Award | 135,000 | $27 |
| Aug 12, 2026 | Ferguson James J. III · officer: Chief Medical Officer | A-Award | 102,400 | $0.00 |
| Aug 12, 2026 | Rodman David Malcom · officer: Chief Medical Officer | Sale | 2,170 | $27 |
| Jul 23, 2026 | Warren Eric · officer: Chief Commercial Officer | M-Exempt | 7,438 | $13 |
| Jul 23, 2026 | Warren Eric · officer: Chief Commercial Officer | Sale | 7,438 | $27 |
| Jul 20, 2026 | Rodman David Malcom · officer: Chief Medical Officer | Sale | 416 | $27 |
| Jul 20, 2026 | Rodman David Malcom · officer: Chief Medical Officer | M-Exempt | 416 | $15 |
| Jul 15, 2026 | Rodman David Malcom · officer: Chief Medical Officer | Sale | 6,349 | $27 |
| Jul 15, 2026 | Rodman David Malcom · officer: Chief Medical Officer | Sale | 14,058 | $28 |
| Jul 15, 2026 | Rodman David Malcom · officer: Chief Medical Officer | M-Exempt | 6,349 | $1.08 |
| Jul 15, 2026 | Rodman David Malcom · officer: Chief Medical Officer | M-Exempt | 4,167 | $14 |
| Jul 15, 2026 | Rodman David Malcom · officer: Chief Medical Officer | M-Exempt | 3,542 | $10 |
| Jul 15, 2026 | Congleton Jon · director, officer: Chief Executive Officer | Sale | 10,700 | $27 |
| Jul 10, 2026 | Rodman David Malcom · officer: Chief Medical Officer | Sale | 2,171 | $30 |
| Jul 10, 2026 | Rodman David Malcom · officer: Chief Medical Officer | M-Exempt | 2,171 | $16 |
| Jun 30, 2026 | Congleton Jon · director, officer: Chief Executive Officer | Sale | 58,000 | $26 |
| Jun 30, 2026 | Congleton Jon · director, officer: Chief Executive Officer | Sale | 17,000 | $27 |
Institutional positioning
13F filings over the trailing two quarters
New 68Increased 190Reduced 123Sold out 25
| Filer | Action | Shares | Filed |
|---|---|---|---|
| Catalys Pacific, LLC | Unchanged | 7,903,838 | Aug 5, 2026 |
| CATALYS PACIFIC, LLC | Unchanged | 7,903,838 | May 14, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 7,692,750 | Aug 14, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Increased | 7,692,750 | May 15, 2026 |
| BlackRock, Inc. | Increased | 5,887,038 | Aug 7, 2026 |
| Samsara BioCapital, LLC | Unchanged | 5,871,018 | Aug 14, 2026 |
| SAMSARA BIOCAPITAL, LLC | Unchanged | 5,871,018 | May 15, 2026 |
| FMR LLC | Reduced | 4,861,104 | May 15, 2026 |
| FMR LLC | Reduced | 4,511,689 | Aug 13, 2026 |
| BLACKROCK, INC. | Increased | 4,481,582 | May 13, 2026 |
| STATE STREET CORP | Increased | 4,141,636 | Sep 22, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | New Position | 3,958,000 | Aug 14, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Increased | 3,359,068 | May 15, 2026 |
| CAPTION MANAGEMENT, LLC | Increased | 3,273,400 | May 15, 2026 |
| STATE STREET CORP | Reduced | 2,935,940 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Oct 20, 2026